May 29, 2019
The Japan arm of Sanofi said on May 28 that iGlarLixi, a combination of insulin glargine and the GLP-1 receptor agonist lixisenatide, was shown to be effective in two Japanese PIII studies in patients with type 2 diabetes inadequately controlled...read more